Crinetics Pharmaceuticals (CRNX) Looks Fully Valued As Vertex Agrees $85 Per Share Deal

Simply Wall St.18:33

AdvertisementVertex acquisition terms and what they mean for Crinetics shareholders Crinetics Pharmaceuticals (CRNX) stock is in focus after Vertex Pharmaceuticals agreed to acquire the company in a ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2651715457?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-07-15 18:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2651715457","market":"us","top_or_hot":-1,"title":"Crinetics Pharmaceuticals (CRNX) Looks Fully Valued As Vertex Agrees $85 Per Share Deal","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementVertex acquisition terms and what they mean for Crinetics shareholders Crinetics Pharmaceuticals (CRNX) stock is in focus after Vertex Pharmaceuticals agreed to acquire the company in a ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crnx/crinetics-pharmaceuticals/news/crinetics-pharmaceuticals-crnx-looks-fully-valued-as-vertex\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Crinetics Pharmaceuticals (CRNX) Looks Fully Valued As Vertex Agrees $85 Per Share Deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCrinetics Pharmaceuticals (CRNX) Looks Fully Valued As Vertex Agrees $85 Per Share Deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-15 18:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crnx/crinetics-pharmaceuticals/news/crinetics-pharmaceuticals-crnx-looks-fully-valued-as-vertex><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementVertex acquisition terms and what they mean for Crinetics shareholders Crinetics Pharmaceuticals (CRNX) stock is in focus after Vertex Pharmaceuticals agreed to acquire the company in a ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crnx/crinetics-pharmaceuticals/news/crinetics-pharmaceuticals-crnx-looks-fully-valued-as-vertex\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999001176.USD","symbol_name":"United Global Healthcare Acc USD","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crnx/crinetics-pharmaceuticals/news/crinetics-pharmaceuticals-crnx-looks-fully-valued-as-vertex","article_id":"2651715457","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crnx/crinetics-pharmaceuticals/news/crinetics-pharmaceuticals-crnx-looks-fully-valued-as-vertex","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2651715457","pubTimestamp":1784111595,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Vertex acquisition terms and what they mean for Crinetics shareholders\nCrinetics Pharmaceuticals (CRNX) stock is in focus after Vertex Pharmaceuticals agreed to acquire the company in a cash deal valuing Crinetics at about $10b, or $85 per share.\nThe transaction, announced on July 6, 2026, would make Crinetics a wholly owned subsidiary of Vertex if it closes. The financing would be supported by a mix of cash, debt, and committed bridge funding.\nSee our latest analysis for Crinetics...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999001176.USD":"United Global Healthcare Acc USD","IBB":"生物科技指数ETF-iShares Nasdaq","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","IDNA":"iShares Genomics Immunology and Healthcare ETF","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BZ9MQY76.HKD":"FTGF CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (HKD) ACC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IBBQ":"Invesco Nasdaq Biotechnology ETF","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","BIB":"Ultra纳斯达克生物科","LU1674673428.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AC\" (USD) ACC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","CRNX":"Crinetics Pharmaceuticals Inc.","BK4007":"制药","IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BK4023":"应用软件","LU0757428866.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AE\" (USD) ACC","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4532":"文艺复兴科技持仓","VRTX":"福泰制药","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU1815336091.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AUP\" (USD) INC","BBH":"VanEck Biotech ETF","PBE":"INVESCO BIOTECHNOLOGY & GENOME ETF","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","BK4567":"ESG概念","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU1778281490.HKD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (HKD) INC","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","BK4139":"生物科技","LU0058720904.USD":"联博国际健康护理基金A","LU1069344957.HKD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","VERX":"Vertex, Inc."},"translate_title":"随着 Vertex 同意每股 85 美元的交易，Crinetics Pharmaceuticals (CRNX) 看起来完全估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VERX":1.5,"IDNA":0.6,"PBE":0.6,"BIB":0.6,"IBB":0.6,"VRTX":1.5,"BBH":0.6,"CRNX":1.5,"IBBQ":0.6},"content_text":"AdvertisementVertex acquisition terms and what they mean for Crinetics shareholders Crinetics Pharmaceuticals (CRNX) stock is in focus after Vertex Pharmaceuticals agreed to acquire the company in a cash deal valuing Crinetics at about $10b, or $85 per share. The transaction, announced on July 6, 2026, would make Crinetics a wholly owned subsidiary of Vertex if it closes. The financing would be supported by a mix of cash, debt, and committed bridge funding. See our latest analysis for Crinetics Pharmaceuticals. Crinetics Pharmaceuticals’ share price has surged in recent months, with a 30-day share price return of 142.85% and a 90-day share price return of 110.49%. The 1-year total shareholder return of 162.99% and 3-year total shareholder return above 3x suggest strong momentum building into the Vertex acquisition news. If this kind of deal activity has your attention, it may be a good moment to look at other healthcare-focused opportunities and see what stands out in the 40 healthcare AI stocks. Crinetics now trades just below the US$85 cash offer and slightly above the average analyst target of US$82.50. This raises a simple question: how much upside, if any, is left for shareholders at these levels? Most Popular Narrative: 7% Undervalued The most followed narrative currently places Crinetics Pharmaceuticals’ fair value at $90 per share, modestly above the last close at $83.71, which helps explain why some investors still see residual value beyond the $85 Vertex offer.  The assumed bullish price target for Crinetics Pharmaceuticals is $90.0, which represents up to two standard deviations above the consensus price target of $82.5. This valuation is based on what can be assumed as the expectations of Crinetics Pharmaceuticals's future earnings growth, profit margins and other risk factors from analysts on the bullish end of the spectrum.  Read the complete narrative. Want to understand why this narrative still points above the deal price? It leans on rapid revenue expansion, margin repair, and a premium future earnings multiple. Curious how those moving parts add up to that $90 figure. Result: Fair Value of $90 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this Crinetics Pharmaceuticals narrative could be knocked off course if the acromegaly opportunity proves smaller than modeled or if payer policies tighten access. Find out about the key risks to this Crinetics Pharmaceuticals narrative. Next Steps With Crinetics Pharmaceuticals presenting both risks that worry investors and rewards that keep them optimistic, it makes sense to move quickly, review the details, and weigh the evidence for yourself using the 2 key rewards and 2 important warning signs. Looking for more investment ideas beyond Crinetics Pharmaceuticals? If the Crinetics Pharmaceuticals story has sharpened your focus, do not stop here. Use the Simply Wall St Screener to spot other stocks that fit your style.  Target potential value opportunities by reviewing companies that appear mispriced on quality and fundamentals in the 44 high quality undervalued stocks. Prioritise resilience by checking stocks with more robust financial profiles using the solid balance sheet and fundamentals stocks screener (48 results). Hunt for lesser known stories that still meet strict quality filters with the screener containing 20 high quality undiscovered gems.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2651715457","isCrawlerRequest":true}